AUTHORS
Charan Thej Reddy Vegivinti, MD, MBBS, Denai Milton2, Lu Dai3, Pei Lin, MD4, Behrang Amini, MD, PhD5, Melody Renee Becnel, MD6, Mahmoud R. Gaballa, MD7, Gregory P. Kaufman, MD8, William Matsui, MD9, Meera Mohan, MD, MS10, Robert Orlowski, MD, PhD11, Oren Pasvolsky, MD12, Krina Patel Jr, MD, MSc13, Neeraj Saini, MD14, Sheeba Koshy Thomas, M.D.15, Donna Marie Weber, MD16, Sarvari V. Yellapragada, MD17, Qaiser Bashir18, Muzaffar Qazilbash, MD19, Jing Christine Ye, M.D., MSc20
AFFILIATIONS
1 The University of Texas MD Anderson Cancer, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States, The University of Texas MD Anderson Cancer, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer, Houston, Texas, United States
ABSTRACT
Background: Extramedullary disease (EMD) in multiple myeloma (MM) per IMWG definition is a biologically aggressive manifestation associated with historically poor outcomes. Data on clinical outcomes are limited in patients treated with novel therapies. We comprehensively characterized clinical outcomes in a real-world MM/EMD cohort stratified by EMD subtypes based on de novo and secondary (relapsed) diseases.
Methods: We retrospectively reviewed MM patients (pts) with EMD treated at a single institution from June 2021 to February 2026. Demographics, disease characteristics, treatments, response, and survival measures were collected. Endpoints included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and duration of response (DoR). OS, PFS, and DoR were estimated using the Kaplan-Meier method and groups were compared by the log-rank test..
Results: 71 pts were identified (62 pts biopsy proven, 9 pts per imaging), 19 (27%) with de novo EMD, 52 (73%) with secondary EMD. Median age was 61.7 years at the time of EMD diagnosis; 75% were male. Median time from MM diagnosis to secondary EMD was 65.7 months. Visceral involvement was identified in 42% pts (53% de novo, 38% secondary); multiple EMD lesions in 48% pts (47% de novo, 48% secondary). New IMS/IMWG defined high-risk disease was present in 20 of 56 pts (de novo 8 of 17 (47%) pts, secondary 12 of 39 (31%) pts). In the de novo cohort, 4 (21%) pts received autologous stem cell transplantation (ASCT). In the secondary cohort, median prior lines of therapy before secondary salvage were 2.5 (range 1-9) for chemotherapy, 6 (range 1-13) for bispecific, and 4 (range 1-9) for CAR-T.
Median follow-up from EMD diagnosis was 12.8 months (de novo) and 10.8 months (secondary). In the de novo cohort (17 evaluable pts), the best response after the first line therapy was 82% (sCR/CR 35%, VGPR 18%, PR 29%). ASCT was associated with significantly longer median DoR in this cohort (not reached (NR) [95% CI 8.6-NE] vs. 5.4 months [95% CI 0.0-NE] without transplant; p=0.032). In the secondary cohort (42 evaluable pts), the best response after the first EMD salvage therapy was 54% (sCR/CR 40%, VGPR 7%, PR 7%). ORR differed significantly in this cohort by the type of salvage therapy, with CAR-T cell therapy being associated with the highest response rate 89% compared with 53% and 33% for bispecific and chemotherapy respectively (p=0.026). EMD in early relapse (<18 months of MM diagnosis) in this cohort experienced shorter DoR approaching statistical significance (3.2 months vs. NR; p=0.059).
Median PFS from EMD diagnosis was 20.0 months (95% CI: 6.5, NR) in the de novo cohort and 10.1 months (95% CI: 4.9, 29.8) in the secondary cohort. EMD in early relapse was associated with significantly shorter PFS compared to late onset (3.7 vs. 12.6 months; p=0.038). Also in the secondary cohort, a significantly higher percentage of patients receiving chemo salvage therapy progressed or died compared with bispecifics and CAR-T therapies (87% vs. 56% vs. 38%, p=0.038).
Median OS from EMD diagnosis was not reached in the de novo cohort (95% CI 11.4 - NR); 44.0 months for the secondary cohort (95% CI: 10.3- NR). Six months and one year OS rates were 94% and 78% for the de novo cohort and 71% and 61% for the secondary cohort, respectively. Visceral involvement was the dominant adverse prognostic factor for OS in both cohorts of de novo (median: 23.1 months vs. NR; p=0.021) and secondary (median: 5.9 vs. 46.2 months; p=0.006). In the secondary cohort, the mortality rate was lower with CAR-T (22%) than with non-T-cell redirecting chemo therapies (50%), even though differences were not statistically significant.
Conclusion: De novo and secondary EMDs are clinically distinct subtypes with differing presentations and outcomes. Visceral involvement was the dominant adverse prognostic factor for OS in both subtypes. Early relapses with secondary EMD may represent a functional high-risk feature. ASCT was associated with a longer duration of remissions in pts with de novo EMD. CAR-T therapy as salvage treatment was associated with higher response rates, longer DoR, and numerically lower death rate. These findings are hypothesis generating for future studies supporting subtype-specific management approaches for patients with EMD.
DISCLOSURES
Charan Thej Reddy Vegivinti, MD, MBBS: No relevant conflicts of interest to declare.